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ABSTRACT 
Context.  Menstrual cycle characteristics may be associated with risk for cardiovascular disease. 
Objective.  To describe the relationships between menstrual cycle characteristics and daily 
reproductive hormone measures with cardiovascular risk factors in a multiethnic sample of 
middle-aged menstruating women. 
Design and Setting.  Cross-sectional analysis based on the Study of Women’s Health across the 
Nation-Daily Hormone Study.  Associations were examined between cardiovascular risk factors 
and urinary luteinizing hormone, follicle stimulating hormone, estrone conjugates (E1c), and 
pregnanediol glucuronide (Pdg) measured across one menstrual cycle or 50 days.    
Participants.  500 menstruating women who were free from diabetes or past stroke or heart 
attack who met other eligibility criteria, including risk factor measurement within 90 days of 
hormone measurement.  
Main Outcome Measures.  Cardiovascular risk factors, including body mass index (BMI), 
blood pressure, hemostatic factors, and metabolic factors. 
Results.  84% of cycles showed evidence of luteal activity (ELA), presumably evidence of 
ovulation.  There were few differences in risk factors between women with ELA and those with 
no evidence of luteal activity.  Among ELA women, the more elevated the cardiovascular risk 
factors the longer cycle length, but associations adjusting for age and BMI were reduced 
substantially.  Those with lower E1c and PdG averaged across the follicular phase had higher 
waist circumference, triglycerides, insulin, PAI-1, tPA-ag, and Factor VIIc levels in age- and 
BMI-adjusted analyses, ps < .05.    
Conclusions.  In mid-life menstruating women, a longer cycle length was related to 
cardiovascular risk factors, in large part through their common association with BMI.  More 
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favorable levels of metabolic and hemostatic factors were associated with higher levels of 
follicular-phase estrogen, a pattern consistent with a more competent ovary, and higher levels of 
follicular-phase PdG, perhaps of adrenal origin.  These findings suggest that metabolic and 
hemostatic factors may sensitive to hormonal variation during the early perimenopausal 
transition.   
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INTRODUCTION 
It has long been recognized that women are protected from coronary heart disease (CHD) 
prior to the menopause (1).  The extent to which that protection is due to reproductive hormones 
is not known.  One approach to addressing this issue is to evaluate the magnitude of change in 
established CHD risk factors during the perimenopause, compared to another time period, or 
statistically adjusting for chronological aging.  A series of cohort studies that followed this 
strategy suggested that lipid levels change during the perimenopause but that there are no 
consistent increases in blood pressure or weight that are not accounted for by aging (see 2 for 
review).  Nonetheless, these studies had significant limitations.  Most participants were European 
Americans, despite the fact that risk factor levels vary by ethnicity (3).  More recently identified 
risk factors, e.g. hemostatic factors, were not measured.  Only one study measured hormones at 
one point during the menstrual cycle (4), which limited characterization of ovarian function 
across the menstrual cycle.  The importance of the latter is supported by a literature review  (5) 
concluding that heightened CVD risk is associated with menstrual cycle irregularity and 
pregnancy losses and suggesting that abnormal ovarian function during the premenopausal years 
may accelerate risk for CHD (6, 7).    
The present study examined associations between ovarian function during the menstrual 
cycle and cardiovascular risk factors in the Daily Hormone Study (DHS) from the Study of 
Women’s Health across the Nation (SWAN), a multi-ethnic cohort study of pre- and early peri-
menopausal women.  Urinary levels of gonadotropins and sex steroid metabolites were assessed 
daily during one complete menstrual cycle or up to 50 consecutive days, whichever was shorter.  
Blood pressure, weight and waist circumference, metabolic factors, lipids and lipoproteins, and 
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hemostatic and inflammatory markers were measured within a 3-month window of the hormone 
collection.   
A priori categorization of women’s menstrual cycles allowed us to address a number of 
hypotheses.  First, we anticipated that women who had evidence of luteal activity (ELA), 
presumably representing an ovulatory cycle, would have lower levels of CHD risk factors than 
women who experienced presumably anovulatory cycles (NELA).  Second, given that a longer 
cycle length occurs as women approach the perimenopause, as well as in mild reproductive 
disorders, we anticipated that women with longer menstrual cycles, even if ovulatory, would 
have elevated risk factors.  Third, we expected an inverse association between CHD risk factors 
and high estrogen in the follicular phase and high progesterone in the luteal phase, both being 
indicative of a reproductively competent ovary.   We anticipated the findings to be stronger for 
metabolic and perhaps hemostatic factors, but not for blood pressure or weight gain, given the 
results of menopause cohort studies.   
METHODS 
Participants 
 The sample consisted of 500 (153 Caucasian, 107 African American, 36 Hispanic, 92 
Chinese, and 112 Japanese) DHS volunteers whose menstrual cycle urine collection occurred 
within 90 days of cardiovascular risk factor assessment (mean number of days = 37.2, SD = 
26.9) and whose health history was negative for diabetes, heart attack, or stroke.  They were 
identified from the approximately 3200 women enrolled at one of the seven clinical sites.  
SWAN eligibility  criteria included: being from a designated minority for the given site or 
Caucasian; aged 42-52 years; intact uterus and at least one ovary; not currently pregnant or 
breast-feeding; no use in the previous three months of exogenous hormone preparations, which 
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could affect ovarian or pituitary function; and at least one menstrual period within the past three 
months.  Sites used a number of sampling strategies and sampling frames to enroll women in 
SWAN (8).    Informed consent was obtained, and all the relevant institutional review boards 
approved the study. 
 The DHS began the first year following baseline evaluation (12). With the exception of 
age, criteria were as above. The four African American sites targeted recruiting approximately 
90 participants, with half African Americans.  The Japanese and Hispanic sites targeted 180 and 
90 participants, respectively, the designated minority, and, the Chinese site targeted 238 
recruiting proportionately more Chinese than Caucasians.  A total of 867 women (259 
Caucasian, 181 African American, 95 Hispanic, 155 Chinese, and 177 Japanese women) 
completed a daily specimen collection across the menstrual cycle or 50 days.  Of these women, 
840 had sufficient data to allow determination of whether there was evidence of luteal activity 
(see definition below).  Comparisons of the 840 eligible participants, 247 eligible women who 
did not participate, and 113 eligible women with incomplete collections showed no differences 
by pre vs. perimenopausal status, smoking history, or body mass index (BMI) or serum 
hormones other than follicular stimulating hormone (FSH).  DHS participants were slightly 
younger (by ½ year), of Japanese and Chinese origin, less educated, and had lower serum FHS 
levels, relative to the others.  . 
Specimen Collection 
 Women collected specimens beginning with the first day of menstrual bleeding, if 
possible, and ended on the first day of bleeding of the subsequent cycle or after 50 days, 
whichever occurred first.  They stored their samples in a non-frost-free freezer.  When collection 
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was completed, urine specimens were transported on ice to the CLASS Laboratory at the 
University of Michigan for analysis (9 for details of the protocol).   
Hormone Measurement 
 Specimens were glycerol-preserved to permit measurement of uLH and uFSH over long 
storage periods (10) and to prevent interference with the estrone conjugates (E1c), and 
pregnanediol glucuronide (Pdg) assays (11, 12).  Samples were normalized for the amount of 
creatinine in each specimen and expressed per milligram creatinine.    uLH, uFSH, E1c, and Pdg 
were assayed using newly adapted chemiluminescent assays configured to be compatible with 
the ACS-180 Autoanalyzer (CIBA-Corning) (9).  For uFSH, the inter- and intra-assay 
coefficients of variations (CVs) were 11.4% and 3.8%, respectively.  For uLH, the inter- and 
intra-assay CVs were 10.9% and 4.6%, respectively.  For E1c, the minimum detectable 
concentration was 0.1 ng/ml, and the inter- and intra- assay CVs for the E1c were 11.5% and 
8.1%, respectively.  For Pdg, the minimum detectable concentration was 0.0001 ng/ml, and the 
inter- and intra-assay CVs were 17.8% and 7.7%, respectively. 
 Serum hormone levels were collected at the annual examinations within the early 
follicular phase days 2 to 7 (13).  .  Serum estradiol (E2) concentrations were measured with a 
modified, off-line ACS:180 (E2-6) immunoassay.  Inter- and intra-assay coefficients of variation 
averaged 10.6% and 6.4%, respectively, and the lower limit of detection was 1 pg/ml. 
Testosterone concentrations were evaluated with the ACS:180 total testosterone assay modified 
to increase precision in the low ranges.  Inter- and intra-assay coefficients of variation were 
10.5% and 8.5%, respectively, and the lower limit of detection was 2 ng/dl.  Serum 
dehydroepiandrosterone sulfate (DHEAS) concentrations involved competitive binding of 
dimethyl-acridinium ester with to a commercially available anti-DHEAS antibody and a solid 
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phase conjugated to paramagnetic particles.  Inter- and intra-assay coefficients of variation for 
DHEAS were 11.3% and 7.6%, respectively, and the lower limit of detection was 2 ug/dl.   
Measurement of Menstrual Cycle Characteristics 
   Women were categorized in the following groups: women who had evidence of luteal 
activity (ELA) and women who had no evidence of luteal activity (NELA), with the latter group 
further divided into those who ended the cycle collection with a menstrual bleed (NELA-bleed) 
vs. no bleed (NELA-no bleed).  The dichotomous determination of luteal activity was based on 
having the algorithm developed by Kassam et al. (14) and modified for use in SWAN (9).  The 
algorithm defined a cycle-specific baseline of Pdg using a 5-day moving average and considered 
a three-fold increment over the nadir 5-day average Pdg that was sustained for a minimum of 3 
days to be consistent with ovulation.  The Kassam algorithm was validated against weekly serum 
progesterone determination from a test sample of midreproductive, regularly cycling women.  
The probable day of the luteal transition in ELA cycles was assessed using a modified version 
(9) of previously developed algorithms of Waller et al. and Baird et al.  (15, 16) and was based 
on an increase in the ratio of E1c/Pdg followed by an immediate decrease in the ratio.  These 
assessments allowed us to divide cycles into follicular (all days prior to the day of the luteal 
transition, day 0) and luteal (all days after the day of the luteal transition) phases.  The modified 
Kassam et al. algorithm had 98% sensitivity and 96% specificity for the detection of ELA status, 
when compared to a panel of 6 expert raters, and the algorithmic-derived day of luteal transition 
agreed with the experts to within 3 days in 92% of the ELA collections (9).   
97% of women provided at least 80% of all possible cycle days and were considered to 
have adequate data for characterization of their menstrual cycle.  Daily hormone concentrations 
were averaged within the follicular and luteal phases, using the trapezoidal rule.  Cycles missing 
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hormones for two or more consecutive days were omitted from the analyses of integrated 
hormones.  Integrated hormones were calculable for 93.0% of ELA cycles.  Among ELA 
women, cycle length was categorized into <24 days; 25-32 days; and > 33 days. 
Cardiovascular Risk Factor Measurement 
 Risk factors were measured if they were predictors of coronary events in women or if 
available evidence suggested that they were influenced by hormonal factors   Because of the 
DHS began one year after SWAN baseline examination, risk factor data were from the first 
annual follow-up for all but 3 women.    The blood draw for risk factor assays occurred after a 
minimum 10-hour fast between day 2-5of the follicular phase to allow for a reasonable 
standardized hormonal milieu among women still menstruating.  Samples were maintained at 4º 
C until separated, frozen at -80º C, and shipped on dry ice to the central laboratory (Medical 
Research Laboratories, Highland Heights, Kentucky, USA), which is certified by the  Centers for 
Disease Control Lipid Standardization Part III program  (17). All lipid and lipoprotein fractions 
were analyzed on EDTA treated plasma.  Total cholesterol and triglycerides were analyzed by 
enzymatic methods and HDL-C was isolated using heparin-2M manganese chloride (18).  Serum 
insulin was measured using RIA (DPC Coat-a-count, Los Angeles, CA) procedure and 
monitored as part of the monthly quality assurance program by the Diabetes Diagnostic 
Laboratory at the University of Missouri.  Glucose was measured using a hexokinase-coupled 
reaction on a Hitachi 747-200 (Boehringer Mannheim Diagnostics, Indianapolis, IN).   Lp(a) was 
quantified by competitive ELISA (19).  Fibrinogen and Factor VII were measured in frozen 
citrated plasma using a clot-based turbidometric detection system, with Factor VII assay using 
Factor VII deficient plasma in preparing the standard curve.  tPA-ag was measured in plasma 
using a double antibody in an enzyme-linked immunosorbant assay (American Diagnostica, 
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Greenwich, CT), with a human single chain tPA-ag as a standard calibrated against an 
international standard (Hertfordshire, England).  PAI-1 was measured using a solid phased 
monoclonal antibody and an enzyme labeled goal second antiserum for detection (American 
Diagnostica, Greenwich, CT).  CRP-hs was measured using an ultra-sensitive rate 
immunoephelometry (Dade-Behring, Marburg, Germany).    
Waist circumference (narrowest part of torso) was measured over undergarments.  Two 
blood pressure measurements were taken using a standard mercury column when seated after a 
minimum of five minutes of rest and were averaged.  The technicians were certified for their 
performance and compliance with standard SWAN protocol before collecting the physical 
measures.  Current smoking status (yes/no) was assessed by self-report.  Height in centimeters 
and weight in kilograms were measured and body mass index (BMI) was calculated by dividing 
weight by the square of height in meters. 
Statistical Analyses  
Skewed variables were log transformed prior to analyses, i.e. integrated hormones, 
triglycerides, Lp (a), glucose, insulin, PAI-1, and CRP-hs.  Tables present untransformed 
medians and interquartile ranges for logged transformed variables and means and standard 
deviations for the remaining risk factors.  Women who were on lipid lowering medications 
(N=5) were excluded from the lipid analyses, and women on hypertensive medication (N=51) 
were excluded from the blood pressure analyses.  Study hypotheses were analyzed with a series 
of t-tests and ANOVAs for continuous variables, and chi square tests for categorical variables 
comparing the cardiovascular risk factors of ELA and NELA women; the NELA-bleed and 
NELA-no bleed women; and three cycle length categories among ELA women.  Age-adjusted 
partial correlation coefficients described the associations between the daily integrated hormone 
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measures and risk factors.     Additional partial correlations were adjusted for age, BMI, and 
smoking; the 17 women without BMI data were excluded from this analysis.  The interval 
between the interval between measurements of menstrual cycle characteristics and risk factors 
was not associated with any cardiovascular risk factors and is not presented.  To test whether the 
significant age- and BMI-adjusted associations between risk factors and menstrual cycle 
characteristics and hormones varied by ethnic group, we also conducted regression analyses 
including the interaction of ethnicity and the predictor variable in the model along with age, 
BMI, ethnicity, and predictor variable. Unless noted otherwise, the results of the full covariate 
analysis and that of age and BMI were the same and associations did not vary by ethnic group. P-
values <.05 were considered statistically significant. 
RESULTS 
 Table 1 shows the characteristics of the study sample.  By design women were from 
diverse ethnic backgrounds.  Most women had more than a high school education, were early 
perimenopausal (bleeding within the last 3 months but some self-reported irregularity in the past 
year), and had ELA cycles.    
Cardiovascular Risk Factors according to Evidence of Luteal Activity  
 The proportions of women in each ethnic group did not vary between ELA and NELA 
status, p = .31.  Women classified as having ELA cycles had lower BMI, waist circumference, 
diastolic blood pressure, and fibrinogen, compared to women classified as having NELA cycles 
(Table 2; age-adjusted).  Further adjustment for BMI did not alter the results for diastolic blood 
pressure and fibrinogen.   
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Cardiovascular Risk Factors according to Length of Menstrual Cycle 
Among women who with ELA cycles, 65 had short cycles, 51 had long cycles, and 304 
had intermediate length.  Cycle length varied by ethnicity, with more Hispanics having long 
cycles relative to Chinese or Japanese (30.0% vs.6.3% and 7.1% respectively), with African 
Americans and Caucasians intermediate (16.7 % and 12.6% respectively).  Longer cycle length 
was associated with higher BMI, waist circumference, blood pressure, triglycerides, glucose, 
insulin, fibrinogen, tPA-ag, Factor VII, and CRP-hs levels and lower HDL-C levels, after age-
adjustments (Table 3). When adjusted for BMI, triglycerides and CRP-hs remained elevated 
among the long cyclers.  Length of the luteal phase was positively associated with only 
fibrinogen (r= .11, p = .03). 
Cardiovascular Risk Factors according to Integrated Hormones during the Follicular and 
Luteal Phases  
 E1c Concentrations: Among women classified as having an ELA cycle, higher E1c 
concentrations during the follicular phase were associated with lower BMI, waist circumference, 
apoB, triglycerides, Lp(a),  glucose, insulin, PAI-1, tPA-ag, and CRP-hs, with the associations 
remaining significant for waist circumference, triglycerides, Lp(a), insulin, and  PAI-1 in the 
age- and BMI-adjusted analyses (Table 4).  The age- and BMI-adjusted associations between 
integrated E1c concentrations during the follicular phase and Lp(a), and PAI-1 varied by 
ethnicity.  E1c concentrations were inversely associated with Lp(a) among  whites and Chinese, 
but positively associated among Japanese women.  E1c concentrations were inversely associated 
with PAI-1 among Chinese and whites, but positively associated among African Americans.   
The daily E1C concentrations averaged within the luteal phase were only associated with 
lower PAI-1 in the age- and BMI-adjusted analyses.  
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PdG Concentrations: As expected, higher daily Pdg concentrations averaged within the 
luteal phase were associated with lower BMI, waist circumference, blood pressure, triglycerides, 
Lp(a), insulin, PAI-1, tPA-ag, Factor VII, and CRP-hs in age-adjusted analyses.  The association 
with systolic blood pressure was strongest for Hispanic women.  However, higher daily Pdg 
concentrations were only associated with lower tPA-ag in the age- and BMI-adjusted analyses.  
Unexpectedly, lower Pdg concentrations averaged within the follicular phase were 
associated with all but one risk factor.    Age- and BMI-adjusted analyses showed that higher Pdg 
measured during the follicular phase was associated with lower waist circumference, 
triglycerides, insulin, PAI-1, tPA-ag, and Factor VII (Table 4).    
Other Urinary Hormones:  Women with lower risk factor levels had higher uFSH and 
uLH concentrations measured during either phase.  However, following age- and BMI-
adjustments, few risk factors were associated with uFSH and uLH concentrations measured in 
both phases.   
Other Relevant Data 
 Because of the unexpected association between cardiovascular risk factors and urinary 
Pdg concentrations during the follicular phase, we examined the associations among the urinary 
hormone levels by phase.   Among women who had ELA cycles, there were strong associations 
between each of the urinary concentrations across phases, rs > .57.  Urinary E1c concentrations 
in both the follicular and luteal phase were similarly correlated with serum DHEAS (rs = .17 and 
.15, ps < .002, respectively), but were only associated with serum E2 when measured in the 
follicular phase (r = .17, p < .001).  Pdg concentrations were more strongly associated with 
serum DHEAS when measured during the follicular than luteal phase (r = .31, p < .001 vs r = 
.09, p = .09).  Pdg concentrations during the luteal phase were associated negatively with serum 
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testosterone (r = -.14, p = .005).  Age-and BMI-adjusted correlations showed that follicular phase 
serum E2 was associated significantly with higher HDL-C (r=.13, p = .004) and fibrinogen 
(r=.14, p = .003) and lower fasting glucose (r = -.09, p = .05); testosterone with higher HDL-C 
(r=.11, p = .02) and tPA (r=.10, p < .05); and DHEAS with higher fasting glucose (r = .13, p = 
.004). 
DISCUSSION 
Our study tested the hypotheses that higher levels of risk factors would be apparent 
among women classified as having a NELA cycle, relative to women classified as having an 
ELA cycle, and among women with a longer cycle length among women classified as having an 
ELA cycle.  In contrast to expectations, women who were classified as having an ELA vs. NELA 
cycle exhibited few differences in cardiovascular risk factors and the associations between longer 
cycle length and increased cardiovascular risk factors among ELA women were primarily 
accounted for by BMI differences by cycle length.  In a larger sample of ELA women, we 
reported longer cycle length and lower whole cycle uLH, uFSH, and Pdg excretion in obese and 
overweight women, compared to normal weight women (20).   
There was partial support for a third hypothesis.  Pdg concentrations were inversely 
associated with elevated risk factor levels, but unexpectedly in both the luteal and follicular 
phase.   Age- and BMI- adjusted associations were statistically significant for more risk factors 
when PdG was measured in the follicular than in the luteal phase (6 vs 1 risk factor associations).  
The source of Pdg concentrations during the follicular phase is likely to be adrenal rather than 
ovarian (21).    In support of this interpretation, our results showed that urinary Pdg 
concentrations were more related to the adrenal hormones in the serum measured during the 
follicular than the luteal phase.   Alternatively, Pdg in the very early follicular phase is the result 
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of delayed excretion from the prior luteal phase.  Thus, high rates of progesterone production in 
the prior luteal phase or a foreshortened follicular phase could increase the average follicular 
phase Pdg levels.    
As anticipated, higher daily E1c concentrations during the follicular phase were 
associated with lower levels of BMI, adjusted for age, and waist circumference, triglycerides, 
Lp(a), insulin, and PAI-1, adjusted for BMI and age.    The findings imply that women who have 
a reproductively competent ovary in midlife, as evidenced by high levels of E1c during the 
follicular phase and evidence of luteal activity, are at lower risk for cardiovascular disease, 
primarily through lower levels of metabolic and hemostatic factors.   
An advantage of the daily assessment of urinary hormone metabolites is its better 
approximation of women’s overall exposure to hormones during a menstrual cycle, in contrast to 
a single blood draw during the very early follicular phase, per SWAN core protocol, when 
estrogens and progesterone are known to be particularly low and have less variability than later 
in the cycle.  Our results showed stronger and more theoretically consistent associations with 
urinary hormone metabolites than with serum hormone measures, although the serum hormones 
were measured concurrently with the cardiovascular risk factors.  It should be noted that an index 
of free circulating testosterone (not measured in DHS) was also associated with elevated risk 
factors, especially the metabolic factors in the full SWAN cohort (22-23).     
One can posit that obesity in mid-life can lead to longer cycles and suppressed 
reproductive hormones, even when cycles are presumed to be ovulatory, which, in turn, lead to 
alterations in other CHD risk factors.  Adipose tissue secretes a number of adipocytokines, such 
as leptin, which are known to influence hypothalamic-pituitary-ovarian function (24).  Thus, 
increased adiposity per se may have an adverse effect on reproductive hormones and menstrual 
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cycles.  Studies demonstrating improvement in fertility and reproductive hormone secretion with 
weight loss support this concept (25, 26). 
Another possibility is that lower reproductive hormone levels in midlife lead to 
increasing levels of risk factors, including weight, such that obesity is not the initiating event.  
Arguments against this model are that the perimenopausal transition is not associated with 
weight gain, beyond the effect of chronological aging (2), and that weight reduction 
interventions lead to improvement in other cardiovascular risk factors (27) and menstrual 
cyclicity (25, 26).   
Finally, obesity in mid-life may influence the reproductive and metabolic systems 
independently.   The fact that low E1c levels observed during the follicular phase were 
associated with metabolic risk factors and some hemostatic factors, independent of BMI, is 
consistent with this possibility.  Longitudinal measures of hormones, cardiovascular risk factors, 
and menstrual cycle characteristics will permit us to support or refute these models as we 
continue to follow the enrolled women.   
 The study has a number of limitations and strengths.  One single menstrual cycle may not 
be representative of cycles in the months surrounding the time of cardiovascular risk factor 
assessment and may account for the few differences between ELA and NELA women’s risk 
factors.  On the other hand, characterizing a complete cycle has considerable advantage over a 
single annual blood draw, even when the annual blood draw is timed very carefully with 
bleeding patterns.  Second, while the modified Kassam algorithm permitted the determination of 
cycles that were presumed to be ovulatory, the cycles classified as having no evidence of clear 
luteal activity were a somewhat heterogeneous mixture of ovulatory and anovulatory menstrual 
cycles.  We did, however, compare the risk factors of women who had no evidence of clear luteal 
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activity according to whether their specimen collections ended with bleeding or not and this 
distinction was not related to cardiovascular risk factors.   Among the strengths of the study are 
the large number of cycles that were characterized, the large number of established and emerging 
cardiovascular risk factors measured, and the multi-ethnic nature of the sample.    
 In sum, evidence of ovulation in a single cycle had minimal association with 
cardiovascular risk factors levels in pre- and peri-menopausal women.  A longer cycle length 
was related to cardiovascular risk factors, in large part through their common association with 
BMI.  Estrone urinary metabolites and Pdg concentrations during the follicular phase were 
associated with metabolic and hemostatic factors, independent of age and BMI, suggesting that 
metabolic and hemostatic factors may be most sensitive to change during the perimenopausal 
transition.  Characterization of hormonal exposure across the menstrual cycle phases provides 
unique information about risk factors associated with later cardiovascular disease.   
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Table 1. Demographic and menstrual cycle characteristics of the sample. 
 
 
% (N) Ethnicity  
 
 
      African American 
 
21.4 (107) 
      Caucasian 30.6 (153) 
  
      Chinese 18.4 (92) 
  
      Hispanic 7.2 (36) 
  
      Japanese 22.4 (112) 
 
% (N) Education 
 
  
       ≤ High school 23.1 (113) 
  
       > High school 76.9 (377) 
 
% (N) Married women 
 
71.3 (356) 
  
Mean (SD) age at hormone collection  47.1 (2.5) 
 
% (N) Site 
 
  
      Detroit area, MI 12.4 (62) 
  
      Boston, MA 13.0 (65) 
  
      Chicago, IL  9.2 (46) 
  
      Oakland, CA 26.0 (130) 
  
      Los Angeles, CA 22.4 (112) 
  
      Newark, NJ 7.2 (36) 
  
      Pittsburgh, PA 9.8 (49) 
 
% (N) Current smoker 
 
11.0 (55) 
 
% (N) Menopausal status at risk factor assessment                      
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      Pre-menopause 
 28.6 (142) 
       
      Early perimenopause 
 
71.4 (355) 
 
% (N) women with ELA cycles1 
  
84.0 (420) 
Mean (SD) Menstrual cycle length (days) among women with 
ELA cycles 
 
28.3 (5.1) 
 
 
1 ELA refers to evidence of luteal phase activity. 
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    Table 2. Unadjusted mean (standard deviation) or median (interquartile range) of  
cardiovascular risk factors according to evidence of luteal phase activity (ELA) versus no evidence 
of luteal phase activity (NELA) 
 
 Menstrual Cycle Status 
 
Age- 
adjusted 
Age- and 
BMI- 
adjusted  
Cardiovascular Risk Factor ELA NELA P - value 
 
P - value 
 
Body composition     
 
     BMI, kg/m2     
 
 
26.3 ± 6.1 
 
28.2 ± 7.1 
 
  .02 
 
- 
 
     Waist circumference, cm  82.7 ± 14.3 87.3 ± 15.2    .02 .21 
 
Blood pressure     
     Systolic, mm Hg 111.6 ± 13.3 116.5 ±15.3 .07 .20 
 
     Diastolic, mm Hg 72.5 ± 9.7 76.3 ± 10.7 .02 .04 
 
Lipids/lipoproteins     
     LDL-C, mg/dL  112.0 ± 29.6 113.2 ± 28.8 .98 .70 
 
     HDL-C, mg/dL  59.4 ± 14.4 60.0 ± 15.7 .95 .46 
 
     Triglycerides, mg/dL 96.0 (73.0–133.0) 99.0 (80.0–137.0) .93 .91 
 
     Apo-B, mg/dL 103.8 ± 23.2 105.3 ± 23.1 .86 .86 
 
     Lp(a), mg/dL 14.0 (4.0-35.0) 13.0 (4.0-32.0) .88 .62 
 
Glucose metabolism     
     Glucose, mg/dL 90.0 (85.0-96.0) 90.0 (85.0-98.0) .89 .59 
 
     Insulin, µlU/mL  8.0 (6.3-10.6) 7.9 (5.8-11.1) .52 .32 
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Inflammatory/hemostatic     
     Fibrinogen, md/dL  266.4 ± 49.8 283.2 ± 57.8 .02 .03 
 
     PAI-1, ng/mL  16.5 (9.0-28.2) 20.2 (11.0-35.2) .06 .20 
 
     tPA-ag, ng/mL 8.0 ± 3.6 8.7 ± 3.9 .30 .55 
 
     Factor VIIc, % 113.0 ± 23.5 116.2 ± 25.5 .52 .81 
 
     CRP-hs, mg/L 1.0 (0.4-3.1) 1.2 (0.5-4.0) .09 .70 
 
 
 
 
 
 
 27
Cardiovascular Risk Factors 28 
 Table 3. Unadjusted mean (standard deviation) or median (interquartile range) of cardiovascular risk 
factors according to cycle length among women with ELA cycles. 
 
 
  
Cycle Length 
 
Cardiovascular  Risk 
Factors 
≤ 24 days 
n = 65 
25-32 days 
n = 304 
≥ 33 days 
n = 51 
Age- 
adjusted 
p-value 
Age- 
and 
BMI- 
adjusted 
p-value 
Body composition      
 
     BMI, kg/m2  
 
24.5 (± 5.0) 
 
26.3 (± 6.0) 
 
29.1 (± 7.2) 
 
  .001 
 
  - 
 
     Waist    
     circumference, cm 
79.5 (± 13.3) 82.5 (± 13.7) 88.0 (± 17.3)   .007 .15 
 
Blood pressure      
     Systolic, mm Hg 108.9 (± 15.0) 111.6 (± 13.1) 115.3 (± 11.5)   .04 .23 
 
     Diastolic, mm Hg 69.9 (± 10.1) 72.9 (± 9.6) 73.4 (± 9.8)   .05 .09 
 
Lipids/lipoproteins      
     LDL-C, mg/dL  107.4 (± 31.6) 113.1 (± 28.9) 110.9 (± 31.2)   .36 .35 
 
     HDL-C, mg/dL 61.9 (± 13.8) 59.8 (± 14.3) 53.8 (± 14.4)   .01 .19 
 
     Triglycerides, 
     mg/dL 
82.0 (66.0-133.0) 96.0 (73.0-131.0) 116.5 (89.0-182.0)  < .0001 .005 
 
     Apo-B, mg/dL  99.0 (± 23.6) 104.0 (± 22.3) 108.2 (± 27.7)   .09 .48 
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     Lp(a), mg/dL  10.0 (4.0-24.0) 15.0 (5.0-35.0) 16.0 (4.0-43.0)   .46 .95 
 
Glucose metabolism      
     Glucose, mg/dL  88.5 (83.0-93.5) 90.5 (85.0-96.0) 90.0 (86.0-98.0)   .003 .16 
 
     Insulin, µlU/mL 7.6 (6.2-10.4) 7.8 (6.2-10.4) 9.0 (6.8-14.2)   .01 .52 
 
Inflammatory/ 
hemostatic 
     
     Fibrinogen, mg/dL 265.4 (± 55.7) 263.7 (± 47.2) 284.8 (± 54.4)   .03 .33 
 
     PAI-1, ng/mL  16.5 (8.0-27.0) 16.3 (9.0-26.7) 18.9 (12.0-34.6)   .12 .67 
 
     tPA-ag, ng/mL  8.1 (± 3.4) 7.7 (± 3.5) 9.8 (± 4.0)   .003 .12 
     Factor VIIc, % 108.2 (± 20.4) 112.7 (± 22.1) 120.8 (± 32.9)   .02 .08 
 
     CRP-hs, mg/L 0.9 (0.3-3.2) 0.9 (0.4-2.5) 2.5 (1.0-8.1) <.0001 .01 
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Table 4. Partial correlation coefficients (adjusted for age) between cardiovascular risk factors at year 
01 and integrated hormone levels within the follicular and luteal phases among women with ELA 
cycles. 
  
uFSH 
 
uLH 
 
Pdg 
 
Estrone 
 
Cardiovascular Risk 
Factor 
Follicular Luteal Follicular Luteal Follicular Luteal Follicular Luteal 
 
Body composition         
 
     BMI 
 
-0.11* 
 
-0.20* 
 
-0.22* 
 
-0.23* 
 
-0.34* 
 
-0.38* 
 
-0.15* 
 
-0.07 
 
     Waist 
     circumference 
-0.15* -0.18* -0.27* -0.25* -0.36*† -0.37* -0.18*† -0.11* 
 
Blood pressure         
     Systolic 0.04 -0.11* -0.04 -0.16* -0.15* -0.11* -0.05 -0.03 
 
     Diastolic 0.04 -0.08 0.01 -0.07 -0.13* -0.09 -0.05 -0.01 
 
Lipids/lipoproteins         
     LDL-C -0.09 -0.15*† -0.10 -0.14* -0.10* -0.04 -0.06 -0.01 
 
     HDL-C 0.12* 0.16* 0.14* 0.15* 0.15* 0.05 0.08 0.03 
 
     Triglycerides -0.08 -0.12* -0.15* -0.16* -0.28*† -0.14* -0.24*† -0.11* 
 
     Apo-B -0.01 -0.08 -0.06 -0.09 -0.14* -0.07 -0.12* -0.06 
 
     Lp(a) -0.08 -0.12* -0.08 -0.06 -0.11* -0.11* -0.15*† -0.09 
 
Glucose metabolism         
     Glucose 0.01 -0.06 -0.12* -0.14* -0.11* -0.04 -0.11* 0.00 
 
     Insulin -0.12* -0.17* -0.23*† -0.19* -0.35*† -0.28* -0.19*† -0.09 
 
Inflammatory/         
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hemostatic 
     Fibrinogen -0.15*† -0.06 -0.18*† -0.09 -0.08 -0.10 0.02 0.01 
 
     PAI-1 -0.10 -0.09 -0.22*† -0.22*† -0.23*† -0.20* -0.14*† -0.16*† 
 
     tPA-ag  -0.02 -0.02 -0.10 -0.06 -0.24*† -0.25*† -0.13* -0.07 
 
     Factor VIIc -0.08 -0.09 -0.07 -0.07 -0.19*† -0.11* -0.08 -0.10 
 
     CRP-hs -0.09 -0.14* -0.19* -0.15* -0.28* -0.22* -0.10* -0.05 
 
 
* p < .0.05 adjusted for age.  † p < 0.05 adjusted for age and BMI 
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